Supplementary Documents of Consolidated Financial Results for the Second Quarter of FY2026

(from April 1, 2026 to September 30, 2026)

November 4, 2026

Securities code：4886 (TSE)

ASKA Pharmaceutical Holdings Co., Ltd.

Note:This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Highlight

FY2026 2Q Apr – Sep (Consolidated)

Net sales	✓ 35.6 billion yen, increased 1.1% YoY Revenue increased on solid performance in the domestic pharmaceutical and animal health businesses.
Cost of sales	✓ 18.8 billion yen, COS ratio increased 1.0 percentage points YoY Increased due to higher purchase prices of products and raw materials, among other factors.
SG&A expenses	✓ 14.0 billion yen, SGA ratio improved 1.2 percentage points YoY The SG&A expense ratio improved as reductions in transportation and storage costs and other expenses offset higher R&D expenses.
Operating profit	✓ 2.7 billion yen, increased 3.5% YoY

FY2026 Consolidated Financial Forecast

Note: No revisions.

Performance forecast	✓ Net sales 73.0 billion yen, up 2.6% YoY ✓ Operating profit 6.2 billion yen, up 6.3% YoY

Statements of Income (Consolidated)

(Millions of yen)	FY2025 Apr - Sep Actual	FY2026 Apr - Sep Actual	Actual +/-	Growth +/-
Net sales	35,253	35,626	373	1.1%
Operating profit	2,648	2,740	92	3.5%
Ordinary profit	2,638	2,862	224	8.5%
Profit attributable to owners of the parent	2,219	2,006	△ 213	△ 9.6%

- ✓ Revenue increased due to solid performance in the domestic pharmaceutical and animal health businesses.
- ✓ Operating profit and ordinary profit increased, despite a higher cost of sales ratio and increased R&D expenses, due to reductions in transportation and storage costs and other expenses.
- ✓ Net income attributable to owners of the parent decreased by 9.6% year on year, mainly due to an increase in deferred income taxes.

Consolidated Sales and Profit by Business Segment

(Millions of yen)

		FY2025 Apr - Sep Actual	FY2026 Apr - Sep Actual	Breakdown	Actual +/-	Growth +/-
Pharmaceutical business (Domestic)	Sales	29,255	29,615	83.1%	360	1.2%
	Profit	3,119	3,297	–	177	5.7%
Animal health business	Sales	3,765	4,125	11.6%	360	9.6%
	Profit	282	276	–	(6)	(2.2)%
Overseas business	Sales	2,133	1,798	5.0%	(335)	(15.7)%
	Profit	131	53	–	(78)	(59.6)%
Other business (clinical testing and medical devices)	Sales	99	87	0.2%	(11)	(12.0)%
	Profit	(15)	(2)	–	13	–
Total Sales		35,253	35,626	100.0%	373	1.1%

- ✓ In the domestic pharmaceutical business, revenue increased as growth in Slinda and RELUMINA, together with solid performance of THYRADIN and RIFXIMA in the internal medicine field and LEUPRORELIN in the urology field, more than offset a decline in DroEthi in the obstetrics and gynecology field.
- ✓ In the animal health business, revenue increased by 9.6% year on year, driven by strong sales of feed additives.
- ✓ In the overseas business, revenue and profit decreased, mainly due to difficulties in procuring active pharmaceutical ingredients for key products.

Sales of Main Products (Pharmaceutical Business)

(Millions of yen)

Area	Category	Products (generic name)	FY2025 Apr - Sep	FY2026 Apr - Sep		FY2026 Apr - Mar		Reference	Notes
			Actual	Actual	YoY	Forecast	YoY	Initial Forecast	
Internal Medicine	Brand-name	**THYRADIN** (levothyroxine)	4,306	4,554	5.7%	9,082	3.5%	9,082	Higher NHI drug price; increased volume
	Brand-name	**RIFXIMA** (rifaximin)	3,880	4,163	7.3%	8,023	1.8%	8,023	NHI price maintained; volume above expectations; October guideline revision to boost prescriptions
	AG	**CANDESARTAN**[1] (candesartan)	4,026	3,597	(10.7)%	7,213	(8.5)%	7,213	Lower NHI drug price; volume remained largely unchanged
	Brand-name	**MERCAZOLE** (thiamazole)	825	881	6.9%	1,745	5.5%	1,745	Higher NHI drug price; volume remained largely unchanged
Obstetrics and Gynecology	Brand-name	**RELUMINA** (relugolix)	5,692	5,838	2.6%	11,340	1.5%	11,340	Lower NHI drug price; increased volume; April guideline revision expected to boost prescriptions
	Generic	**DroEthi** (drospirenone/ethinylestradiol)	4,109	3,854	(6.2)%	7,678	(7.6)%	7,678	Lower NHI drug price; increased volume; approval obtained for the Flex formulation in August
	AG	**FREWELL** (norethisterone/ethinylestradiol)	1,509	1,287	(14.7)%	2,586	(13.0)%	2,586	Lower NHI drug price; decreased volume
	Brand-name	**LUTEUM** (progesterone)	1,095	1,177	7.5%	2,197	(3.2)%	2,197	NHI drug price maintained; volume increased more than expected
	Brand-name	**Slinda** (drospirenone)	119	549	358.1%	1,019	159.9%	1,019	Not listed under the NHI drug price system (contraceptive); volume increased as expected
Urology	Generic	**LEUPRORELIN**[2] (leuprorelin)	1,908	2,222	16.5%	5,096	31.3%	5,596	Lower NHI drug price; focused on switching from the originator product to the SR formulation

[1] Including fixed dose combination

[2] 1.88mg formulation is only for gynecological indications but combined with 3.75mg formulation and SR formulation (11.25mg formulation launched in December 2025)

Sales by Major Business Field (Animal Health Business)

(Millions of yen)


Business field	FY2025 Apr - Sep	FY2026 Apr - Sep		FY2026 Apr - Mar	
	Actual	Actual	YoY	Forecast	YoY
Feed additives Mixed feed Feed materials	2,249	2,739	21.8%	5,069	12.3%
Veterinary pharmaceuticals (livestock and fisheries + CA*)	1,371	1,336	(2.5)%	2,727	3.3%

- ✓ Veterinary pharmaceuticals decreased 2.5% year on year, as strong sales of companion animal (CA) products were offset by lower sales of livestock and fisheries products.
- ✓ Feed additives and other products performed well, with sales increasing 21.8% year on year.
- ✓ For FY2026, sales growth is expected in both feed additives and veterinary pharmaceuticals.


* Companion Animal

Sales Composition and Share of Brand-name Drugs

Sales Composition by Therapeutic Area (FY2026 2Q Apr - Sep)



Share of Brand-name and Generic Drugs




The share of brand-name drugs increased by 3.0 percentage points, driven by growth in Slinda, RIFXIMA, THYRADIN, RELUMINA, and other products.

R&D Status

Trend of R&D expenses

(Millions of yen)



(As of November 4, 2026)

Development code (Generic name) / Indication	Phase
AKP-022 (relugolix combination tablet) Uterine fibroids	Ph III ongoing
AKP-022 (relugolix combination tablet) Endometriosis	Ph III ongoing
LPRI-CF113 (drospirenone) Dysmenorrhea	Ph III ongoing
AKP-SMD106 (Digital therapeutics app[1]) Premenstrual syndrome/premenstrual dysphoric disorder	Specified clinical trial[2] ongoing
AKP-009 (ludaterone acetate) Polyendocrine metabolic ovarian syndrome; PMOS	Preparing clinical trials
MCN-009 (Digital therapeutics app[1]) Irritable bowel syndrome	Confirmatory clinical trial[3] ongoing
AKP-009 (ludaterone acetate) Benign prostatic hyperplasia	Ph II ongoing
AKP-021 (mPGES-1 inhibitor)	Ph I ongoing
AKP-017 (intranasal testosterone)	Preparing clinical trials

1. The regulatory nonproprietary name has not been determined as it is planned to be newly established
2. Equivalent to PhII for ethical pharmaceutical drugs; co-developed with SUSMED, Inc.
3. Equivalent to PhIII for ethical pharmaceutical drugs; co-developed with MICIN, Inc.